Form 4: Vertex Pharmaceuticals Director Upadhyay Reports Stock Transactions

Director Suketu Upadhyay reports acquisition and disposition of Vertex Pharmaceuticals stock and deferred stock units on May 1, 2024.

Summary

• On May 1, 2024, Suketu Upadhyay, a director at Vertex Pharmaceuticals, reported acquiring 1,001 shares of common stock.
• These shares were acquired through a restricted stock unit award that vests on the first anniversary of the grant date.
• On the same day, Mr. Upadhyay disposed of 1,168 shares of common stock in exchange for 1,168 deferred stock units.
• This transaction was related to the vesting of restricted stock units granted on May 1, 2023, and a subsequent deferral under the company's deferred compensation plan.
• Following these transactions, Mr. Upadhyay directly owns 2,559 shares of common stock and 1,402.996 deferred stock units.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by a company director. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Future Outlook

The deferred stock units will be paid out in common stock upon the earliest to occur of (i) termination of Mr. Upadhyay's service on our board of directors, (ii) a change of control of our company and (iii) Mr. Upadhyay's disability or death.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, like directors, who trade in their company's stock. It provides transparency to the market regarding the transactions of those with privileged information.

Stakeholder Impact

• The transactions may have a minor impact on shareholders by slightly altering the ownership structure of the company.
• The deferred compensation plan impacts Mr. Upadhyay's compensation and future stock ownership.

Key Dates